Best Cell Therapy CDMOs in Europe

Last updated: 2026-09-15 · updated as new inspection, certificate, and trial data enters the platform

← All Cell Therapy CDMOs Best Clean FDA History Commercial Scale

Region: USA Europe Asia UK India Switzerland Germany South Korea Japan China

CDMOs tracked

Fully scored

With FDA records

FDA inspections

105

EMA/MHRA GMP certs

For European-manufactured cell therapy programs, Takeda, Merck KGaA / MilliporeSigma (CDMO), and AGC Biologics lead CDMO Signal's ranking of cell therapy CDMOs with confirmed European manufacturing sites. Filtered from the global directory of 64 scored cell therapy CDMOs to 5 with European facility presence. EU and UK manufacturing carry specific regulatory considerations for sponsors: EMA and MHRA GMP certification — which contribute directly to the Signal Score's Quality Compliance pillar — are typically required for material supplied to EU/UK trials or commercial markets, and Qualified Person (QP) release is a distinct process step that doesn't apply to US-only manufacturing. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.

Cell therapy CDMOs manufacture living products — CAR-T, TCR, NK, and stem-cell therapies — where the process is the product. Autologous programs add patient-scheduling and chain-of-identity demands that allogeneic, batch-based programs avoid.

The right cell therapy CDMO depends on autologous vs allogeneic experience, vector sourcing, closed-system processing, and cold-chain logistics. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 13 NAI (no action), 14 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (22), UNITED KINGDOM (22), Denmark (18), Germany (15), Ireland (12).

Last updated 2026-09-15. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

#	CDMO	Signal Score	Quality	FDA · GMP	Capacity	Programs
1	TK Takeda Boston, MA · Zurich, CH	81.9	99.6	4 insp · 18 GMP	—	100 programs
2	MK Merck KGaA / MilliporeSigma (CDMO) Darmstadt, DE · St. Louis, MO	81.8	98.7	2 insp · 2 GMP	—	22 programs
3	AG AGC Biologics Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP	78.6	100.0	2 insp · 23 GMP	Available	2 programs
4	Lonza Basel, Switzerland	76.0	95.7	2 insp · 8 GMP	—	1 programs
5	MB Miltenyi Biotec Bergisch Gladbach, Germany	73.0	100.0	0 insp · 2 GMP	—	8 programs
6	CR Charles River Laboratories Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD	90.9	98.3	8 insp · 11 GMP	Limited	0 programs
7	MN Minaris Advanced Therapies Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP	83.3	99.6	1 insp · 6 GMP	Limited	0 programs
8	SC SCTbio Prague, Czech Republic	81.6	100.0	0 insp · 5 GMP	—	0 programs
9	EF Eurofins CDMO Planegg, DE · San Diego, CA	81.6	100.0	5 insp · 0 GMP	—	0 programs
10	RC RoslinCT Edinburgh, UK · Hopkinton, MA	80.3	99.0	1 insp · 1 GMP	Available	0 programs
11	CF CELLforCURE (SEQENS) Les Ulis, FR	80.3	100.0	0 insp · 4 GMP	—	0 programs
12	SK SK pharmteco Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.	79.5	100.0	—	Available	0 programs
13	NG NecstGen Leiden, NL	78.1	100.0	0 insp · 1 GMP	—	0 programs
14	OR Ori Biotech London, UK	78.1	100.0	0 insp · 1 GMP	—	0 programs
15	CE Celonic Basel, Switzerland	78.1	100.0	0 insp · 1 GMP	—	0 programs
16	XP eXmoor Pharma Bristol, United Kingdom	78.1	100.0	0 insp · 1 GMP	—	0 programs
17	SY Symbiosis Pharmaceutical Services Stirling, United Kingdom	76.8	100.0	1 insp · 9 GMP	—	0 programs
18	CY Cell-Easy Toulouse, FR	76.8	100.0	0 insp · 2 GMP	—	0 programs
19	CN Cellin Technologies Luxembourg, LU	76.8	100.0	0 insp · 1 GMP	—	0 programs
20	HH HiTech Health London, United Kingdom	76.8	100.0	0 insp · 9 GMP	—	0 programs
21	CG Cytiva (Mfg Services) Marlborough, MA · Uppsala, SE	74.0	—	—	—	0 programs
22	LZ Lonza Biologics Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH	73.0	95.7	1 insp · 0 GMP	Limited	0 programs
23	RA Recipharm Advanced Bio Stockholm, Sweden	63.0	—	—	—	0 programs
24	CP Cell and Gene Therapy Catapult Stevenage, United Kingdom	59.0	—	—	—	0 programs
25	EX Excellos La Rochelle, France	59.0	—	—	—	0 programs
26	CZ Cellex Cell Professionals Cologne, Germany	59.0	—	—	—	0 programs
27	CX CellGenix Freiburg, DE	56.5	—	—	—	0 programs

How we score CDMOs →

What to evaluate in a Cell Therapy CDMO

Autologous vs allogeneic

Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model.

Vector & raw materials

Most cell therapies need a viral vector. Confirm whether the CDMO makes vector in-house or coordinates an external supplier, and how that affects timelines.

Closed-system & cleanrooms

Closed, automated processing reduces contamination risk and labor. Ask about cleanroom grade, automation platforms, and parallel-suite capacity.

Cold chain & logistics

Cryopreservation and chain-of-custody are critical for living cells. Evaluate the CDMO's cold-chain and apheresis-to-infusion logistics.

EMA and MHRA regulatory considerations for European-manufactured programs

European manufacturing for biopharma programs typically requires EMA-recognized GMP certification (via the EudraGMDP database) for EU material and MHRA GMP certification for UK material — post-Brexit, these are separate credentials even for CDMOs operating in both. The Signal Score's Quality Compliance pillar weighs EMA + MHRA GMP certificate density directly, so European CDMOs with dense certification typically rank higher on this pillar. Sponsors should verify certificate coverage for the specific manufacturing activity (drug substance vs drug product, dosage form) at the specific facility being considered — GMP certificates are activity-scoped, not blanket.

QP release requirements and how they affect CDMO selection

Every batch of medicinal product supplied to the EU market must be released by a Qualified Person (QP) — a specific regulatory role with statutory responsibility. This adds a process step (and typically a specific QP-service arrangement) that US-only manufacturing does not require. CDMOs with European operations either have in-house QPs (typical for larger diversified players) or coordinate with external QP services. For sponsors running EU trials or supplying EU commercial markets, this is a non-negotiable requirement to plan for. Individual CDMO profile pages capture facility-level detail; QP arrangements specifically are usually confirmed at RFP stage rather than published.

Which European CDMOs also cover FDA (US) regulatory geography?

European CDMOs with US FDA inspection history — indicating US regulatory posture — are candidates for sponsors running programs in both jurisdictions. The Signal Score's Quality Compliance pillar includes FDA inspection classifications, so a European CDMO with a strong FDA record typically ranks higher on that pillar than a European-only competitor. Cross-check with the US region ranking — CDMOs appearing in both rankings have demonstrated regulatory posture across both jurisdictions, which reduces tech-transfer risk for global programs.

Cell Therapy CDMOs — Frequently Asked Questions

Who are the top Cell Therapy CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked Cell Therapy CDMOs include Takeda, Merck KGaA / MilliporeSigma (CDMO), AGC Biologics. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

How many Cell Therapy CDMOs have FDA inspection records?

CDMO Signal tracks 10 Cell Therapy CDMOs with FDA inspection records and 105 EMA/MHRA GMP certificates across the group.

What should I look for in a cell therapy CDMO?

Match the CDMO to your model: autologous needs chain-of-identity and fast turnaround; allogeneic needs scalable batch processing. Confirm vector sourcing, closed-system processing, cold-chain logistics, and a clean FDA and EMA/MHRA record.

Do cell therapy CDMOs make their own viral vectors?

Some do in-house; others coordinate an external vector supplier. In-house vector can shorten timelines and simplify supply, but a strong external partner is common. Check each profile's modality coverage above.

Related modalities

Lentiviral Vector CDMOs CAR-T CDMOs Gene Editing CDMOs

Other Modalities

AAV CAR-T Lentiviral mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy Viral Vector